Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.
But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.
Shares of Cassava fell 18% to $29, erasing $270 million in market value. The company is still worth $1.2 billion even though Tuesday’s troublesome data should erase any investor’s hope that twin Phase 3 studies of simufilam — ongoing but still enrolling participants — will prove successful.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect